Emerg Infect Dis. 2019 Apr;25(4):838-840. doi: 10.3201/eid2504.181554.
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.
Abed Y, Fage C, Lag?e P, Carbonneau J, Papenburg J, Vinh DC, Boivin G.
Abstract
We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.
KEYWORDS:
Canada; Gly407Ser; influenza; influenza B; neuraminidase; oseltamivir; peramivir; resistance; viruses; zanamivir
PMID: 30882323 DOI: 10.3201/eid2504.181554
Free full text
Text-to-speech function is limited to 200 characters
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.
Abed Y, Fage C, Lag?e P, Carbonneau J, Papenburg J, Vinh DC, Boivin G.
Abstract
We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.
KEYWORDS:
Canada; Gly407Ser; influenza; influenza B; neuraminidase; oseltamivir; peramivir; resistance; viruses; zanamivir
PMID: 30882323 DOI: 10.3201/eid2504.181554
Free full text
Detect languageundefined | undefined |
Text-to-speech function is limited to 200 characters